title: Effects of zinc-L-carnosine and vitamin E on aspirin-induced gastroduodenal injury in dogs.
abstract: BACKGROUND
  Nonsteroidal anti-inflammatory drugs frequently cause gastrointestinal (GI) injury. Zinc-L-carnosine has antioxidant, anti-inflammatory, mucosal protective, and healing properties in rodent models and in some human studies of GI injury.
  
  
  OBJECTIVE
  The combination of zinc-L-carnosine and vitamin E attenuates aspirin-induced gastroduodenal mucosal injury.
  
  
  METHODS
  Eighteen healthy random-source Foxhound dogs.
  
  
  METHODS
  In this randomized, double-blinded, placebo-controlled study dogs were treated with placebo (n = 6; 0X group), 30 mg/30 IU (n = 6; 1X group), or 60 mg/60 IU (n = 6; 2X group) zinc-L-carnosine/vitamin E orally every 12 hours for 35 days. Between Day 7 and 35, GI mucosal lesions were induced with aspirin (25 mg/kg p.o. q8h). Mucosal injury lesions (hemorrhage, erosion, and ulcer) were assessed by gastroduodenoscopy on Days 14, 21, and 35 with a 12-point scoring scale.
  
  
  RESULTS
  At baseline (Day -1) gastroscopy scores were not significantly different between groups (mean ± SD: 0X, 4.4 ± 0.8; group 1X, 4.4 ± 0.6; group 2X, 4.2 ± 0.3; P= .55). Gastroscopy scores increased significantly in all groups between Day -1 and Days 14, 21, and 35 (P < .0001). On Day 35, gastroscopy scores were 29.2 ± 5.2 (0X), 27.3 ± 3.7 (1X), and 28.6 ± 3.3 (2X). Mean gastroscopy scores were not significantly different among treatment groups on any of the days (P = .61).
  
  
  CONCLUSIONS
  Administration of the combination of zinc-L-carnosine and vitamin E at 1X or 2X dosing did not attenuate aspirin-induced gastroduodenal mucosal injury.
authors.affiliation: Department of Medical Sciences, School of Veterinary Medicine, The University of Wisconsin-Madison, Madison, WI 53706, USA. miekebaan@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Baan
authors.forename: R G
authors.initials: RG
authors.lastname: Sherding
authors.forename: S E
authors.initials: SE
authors.lastname: Johnson
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002336:Carnosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy*; D004285:Dogs; D004311:Double-Blind Method; D004384:Duodenoscopy / Q000662:veterinary; D004435:Eating / Q000187:drug effects / Q000502:physiology; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010865:Pilot Projects; D018709:Statistics, Nonparametric; D024505:Tocopherols / Q000627:therapeutic use*; D017967:Zinc Compounds / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D017967:Zinc Compounds; C061957:polaprezinc; D002336:Carnosine; D024505:Tocopherols; D001241:Aspirin